Le Lézard
Classified in: Health
Subjects: CCA, FVT

Omnicell to Release Second Quarter 2018 Earnings Results on July 26, 2018


MOUNTAIN VIEW, Calif., July 19, 2018 /PRNewswire/ -- Omnicell, Inc. (NASDAQ: OMCL), a leading provider of medication and supply management solutions and adherence tools for healthcare systems and pharmacies, will hold a conference call on Thursday, July 26, 2018 to discuss the Company's Second Quarter 2018 financial results.

What:

Omnicell Second Quarter 2018 earnings conference call and webcast

When:

July 26, 2018, 1:30 p.m. PT

Who:

Randall Lipps, chairman, president, chief executive officer, and founder Peter Kuipers, chief financial officer

Where:

The conference call can be monitored by dialing 1-800-696-5518 within the U.S. or 1-706-758-4883 for all other locations. The Conference ID # is 7290938. The webcast can be accessed at: http://ir.omnicell.com/events.cfm.

How:

Link to the Omnicell website 15 minutes prior to the call to download necessary audio software.

Replay:

Available starting at 4:30 p.m. PT on July 26, 2018, through 11:59 p.m. PT on September 6, 2018. Dial 1-855-859-2056 within the U.S. and 1-404-537-3406 for all other locations, Conference ID # 7290938.

Omnicell, Inc. logo. (PRNewsFoto/Omnicell, Inc.)

About Omnicell

Since 1992, Omnicell (NASDAQ: OMCL) has been inspired to create safer and more efficient ways to manage medications and supplies across all care settings. Omnicell is revolutionizing the patient medication experience from hospital to home by empowering providers to keep each patient at the center of care. The Company's autonomous approach to medication management leverages a differentiated platform for hardware and workflow software solutions, real-time predictive intelligence, and performance-driven partnerships to help drive operational, financial, and clinical success for customers.

Supporting the highest level of patient safety is essential to excellent patient care. As a leader in medication and supply dispensing automation, central pharmacy automation, IV robotics, analytics software, and medication adherence and packaging systems, Omnicell is focused on delivering solutions for medication availability, affordability, safety, and adherence. Over 4,500 facilities worldwide use Omnicell® automation and analytics solutions to increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety.

Omnicell's innovative medication adherence solutions, used by over 32,000 institutional and retail pharmacies in North America and the United Kingdom, are designed to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions.

For more information about Omnicell, Inc. please visit www.omnicell.com.

OMCL-E

 

SOURCE Omnicell, Inc.


These press releases may also interest you

at 09:35
Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor cancer and rare disease, respectively. CancerVision and...

at 09:30
PossibleNOWtm, the leading provider of enterprise consent and preference management solutions, today announced the launch of a program to enable companies to quickly capture express written consent. This will provide the ability for Third-Party...

at 09:30
Envisagenics, an AI-driven biotechnology company, today announced the publication in the journal Molecular Systems Biology of study results evaluating the company's SpliceCore AI/ML platform in Triple Negative Breast Cancer (TNBC). This study...

at 09:30
Co-Diagnostics, Inc. , a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after the...

at 09:20
Coronis Health, a trusted partner for laboratory and pathology revenue cycle management (RCM), will be a leading voice at the upcoming Executive War College (EWC) 2024 conference from April 30 to May 1 in New Orleans. As the premier forum for...

at 09:18
PRUVN Research LLC, [PRUVN], a leading research organization validating wellness products and services, is excited to announce the results of its recent preliminary study with Max International, investigating the impact of RiboCeinetm supplementation...



News published on and distributed by: